Company profile
Ixchelsis company profile
Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose study in healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://ixchelsis.com
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Revenue range
- $10K+
- Founded
- 2011-01-01
Headquarters
- Headquarters
- Kent, Sandwich, United Kingdom
- Country code
- GB
- Continent
- Europe